Cell line · CVCL_7151
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Drug Screening of Sarcoma Cells: Finding Shared Sensitivities. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Unfolded Protein Response as a Therapeutic Target: 4-(Heptyloxy)phenol Induces Programmed Cell Death in Ewing Sarcoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40376089 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. | J Hematol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inducing Mitotic Catastrophe as a Therapeutic Approach to Improve Outcomes in Ewing Sarcoma. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Cancer-Associated Fibroblast-Like Tumor Cells Remodel the Ewing Sarcoma Tumor Microenvironment. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 37333164 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation. | Cell Rep | 2022 | Cellosaurus cites it, and its Methods give the RRID and name the line | PubMed | |
| WEE1 inhibition augments CDC7 (DDK) inhibitor-induced cell death in Ewing sarcoma by forcing premature mitotic entry and mitotic catastrophe. | Cancer Res Commun | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy. | J Immunother Cancer | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Systematic multi-omics profiling of Ewing sarcoma cell lines. | 2021 | Cellosaurus cites it | DOI | ||
| Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone. | Sci Rep | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. | Cancer Res | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_7151/papers